Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

BACKGROUND: During the last decade, oral bisphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk su...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotté, François-Emery, De Pouvourville, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141385/
https://www.ncbi.nlm.nih.gov/pubmed/21702989
http://dx.doi.org/10.1186/1472-6963-11-151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141385/
https://www.ncbi.nlm.nih.gov/pubmed/21702989
http://dx.doi.org/10.1186/1472-6963-11-151

Ejemplares similares